文献类型：期刊文献

英文题名：Effects of clazosentan, cilostazol, and statins on aneurysmal subarachnoid hemorrhage A protocol for systematic review and meta-analysis

作者：He, Junfang[1];Zhang, Li[2];Yu, Yao[3];Luo, Xinyue[4];Wei, Min[5];Chen, Gen[3,6];Shen, Yanfei[7]

第一作者：He, Junfang

通信作者：Wei, M[1]

机构：[1]Rehabil Ctr Hosp Gansu Prov, Dept Neurol Rehabil, Lanzhou, Peoples R China;[2]Gansu Univ Chinese Med, Affiliated Hosp, Cardiovasc Clin Med Ctr, Ward 3, Lanzhou, Peoples R China;[3]Lanzhou Univ, Sch Basic Med Sci, Pathogens Biol Inst, Lanzhou, Peoples R China;[4]Lanzhou Univ, Clin Med Coll 2, Lanzhou, Peoples R China;[5]Gansu Univ Chinese Med, Affiliated Hosp, 732 Jiayuguan West Rd, Lanzhou, Gansu, Peoples R China;[6]Guilin Med Univ, Basic Med Sch, Guilin, Peoples R China;[7]Gansu Prov Hosp, Lanzhou, Peoples R China

第一机构：Rehabil Ctr Hosp Gansu Prov, Dept Neurol Rehabil, Lanzhou, Peoples R China

通信机构：[1]corresponding author), Gansu Univ Chinese Med, Affiliated Hosp, 732 Jiayuguan West Rd, Lanzhou, Gansu, Peoples R China.|[10735b845793de6ae2b30]甘肃中医药大学第二附属医院;[10735]甘肃中医药大学;

年份：2020

卷号：99

期号：17

起止页码：E19902

外文期刊名：MEDICINE

收录：;Scopus(收录号：2-s2.0-85084568743);WOS:【SCI-EXPANDED(收录号:WOS:000544715800079)】；

基金：This work is supported by the Natural Science Foundation of Gansu Province, China (Grant No. 18JR3RA054).

语种：英文

外文关键词：aneurysmal subarachnoid hemorrhage; cilostazol; clazosentan; network meta-analysis; statins

摘要：Background : Aneurysmal subarachnoid hemorrhage (aSAH) is a disease caused by the infiltration of blood into the subarachnoid space due to the rupture of an intracranial aneurysm. It is a serious cerebrovascular disease, with a mortality rate of about 40% worldwide, which seriously threatens human life and health. Many drugs are used to treat aSAH and its complications, and some have been tested in systematic reviews and have shown good effects. But which drug has the best effect remains unclear. This network meta-analysis (NMA) aims to assess the effectiveness and feasibility of clazosentan, cilostazol, and statins in patients with aSAH. Methods : We will search for EMBASE.com, PubMed, the Cochrane Library, and Web of Science from inception to December 2019. Randomized controlled trials (RCTs) reporting efficacy and safety of clazosentan, cilostazol, and statins compared with the control, or compared with each other for the treatment of aSAH will be included. Two independent reviewers will assess the risk of bias of the included RCTs with the Cochrane "Risk of bias" tool. The pairwise meta-analysis will be performed with the random-effects model. The NMA will be performed in a Bayesian hierarchical framework using Markov Chain Monte Carlo method in WinBUGS 1.4.3. Egger test and funnel plot will be used to assess the publication bias. We will evaluate the quality of evidence for each outcome according to the GRADE approach. Results : The results of this NMA will be submitted to a peer-reviewed journal for publication. Conclusion : This study will summarize up-to-date evidence to compare the efficacy and safety of clazosentan, cilostazol, and statins on aSAH. PROSPERO registration number:CRD42019147523.